cnct19
Cell therapyexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2020 (NCT04232826)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05667506 | Phase 1/Phase 2 (Phase 2) | Jan 6, 2023 | Chinese Academy of Medical Sciences, Juventas Therapeutics, Inc. |
| NCT06316791 | Early Phase 1 (Phase 1) | Dec 14, 2021 | Juventas Therapeutics, Inc., Zhengzhou University |
| NCT04684147 | Phase 2 | Dec 31, 2020 | Chinese Academy of Medical Sciences, Juventas Therapeutics, Inc. |
| NCT04586478 | Phase 2 | Oct 26, 2020 | Chinese Academy of Medical Sciences, Jiao Tong University, Juventas Therapeutics, Inc. |
| NCT04230473 | Phase 1 | Jan 31, 2020 | Chinese Academy of Medical Sciences, Juventas Therapeutics, Inc. |
| NCT04232826 | Phase 1 | Jan 31, 2020 | Chinese Academy of Medical Sciences, Juventas Therapeutics, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Juventas Therapeutics, Inc. | For profit | 6 | 6 | 2 | 2020 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 5 | 0 | 2 | 2020 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Zhengzhou University | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1